Sunshine Biopharma director to leave board after term

Q: What director change did Sunshine Biopharma Inc. (SBFM) disclose?

Sunshine Biopharma Inc. disclosed that director Dr. Andrew Keller notified the company on August 25, 2026 that he will not be seeking or accepting reelection to the Board of Directors when his current term expires at the next annual shareholder meeting.

Q: Did Sunshine Biopharma Inc. (SBFM) report an immediate director resignation?

No. Sunshine Biopharma Inc. reported that Dr. Andrew Keller will serve out his current term and will not seek or accept reelection at the next annual shareholder meeting, rather than resigning immediately.

Q: Which officer signed the Sunshine Biopharma Inc. (SBFM) 8-K about the director change?

The report was signed for Sunshine Biopharma Inc. by Dr. Steve N. Slilaty, Chief Executive Officer, dated August 28, 2026, in accordance with the requirements of the Securities Exchange Act of 1934.

Sunshine Biopharma Inc. (SBFM) reported that on August 25, 2026, director Dr. Andrew Keller informed the company he will not seek or accept reelection to the Board of Directors after his current term ends.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Sunshine Biopharma Inc. (SBFM) reported that on August 25, 2026, director Dr. Andrew Keller informed the company he will not seek or accept reelection to the Board of Directors after his current term ends. His term will expire at the company’s next annual shareholder meeting, at which point he will leave the board.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Emerging growth company, Section 12(b) of the Act, Common Stock Purchase Warrants

3 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 12(b) of the Act regulatory

"Securities registered pursuant to Section 12(b) of the Act"

Common Stock Purchase Warrants financial

"Common Stock Purchase Warrants | SBFMW | The Nasdaq Stock Market LLC"

Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What director change did Sunshine Biopharma Inc. (SBFM) disclose?

Sunshine Biopharma Inc. disclosed that director Dr. Andrew Keller notified the company on August 25, 2026 that he will not be seeking or accepting reelection to the Board of Directors when his current term expires at the next annual shareholder meeting.

When will Dr. Andrew Keller leave the SBFM Board of Directors?

Dr. Andrew Keller’s current term on Sunshine Biopharma Inc.’s Board of Directors will expire at the company’s next annual shareholder meeting. At that time he will not stand for reelection and will leave the board.

Did Sunshine Biopharma Inc. (SBFM) report an immediate director resignation?

No. Sunshine Biopharma Inc. reported that Dr. Andrew Keller will serve out his current term and will not seek or accept reelection at the next annual shareholder meeting, rather than resigning immediately.

Which officer signed the Sunshine Biopharma Inc. (SBFM) 8-K about the director change?

The report was signed for Sunshine Biopharma Inc. by Dr. Steve N. Slilaty, Chief Executive Officer, dated August 28, 2026, in accordance with the requirements of the Securities Exchange Act of 1934.

What is the main purpose of this Sunshine Biopharma Inc. (SBFM) 8-K?

The main purpose is to disclose under Item 5.02 that director Dr. Andrew Keller has notified Sunshine Biopharma Inc. that he will not seek or accept reelection to the Board of Directors when his current term ends at the next annual shareholder meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/28/2026 - 04:06 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:05 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 25, 2026

SUNSHINE BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Colorado

001-41282

20-5566275

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)

333 Las Olas Way

CU4 Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (Zip Code)

(954) 330-0684

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered

Common Stock, par value $0.001	SBFM	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	SBFMW	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 25, 2026, Dr. Andrew Keller, a director of Sunshine Biopharma Inc. (the “Company”), notified the Company that he will not be seeking or accepting reelection to the Board of Directors of the Company upon completion of his current term. Dr. Keller’s current term will expire at the Company’s next annual shareholder meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 28, 2026	SUNSHINE BIOPHARMA INC.


	By: /s/ Dr. Steve N. Slilaty
	Name: Dr. Steve N. Slilaty, Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents